To assess the impact of UCH-L1 depletion on drug response, we incubated three UCH-L1 expressing myeloma cell lines with a series of concentrations of either bortezomib or dexamethasone, and monitored cell viability. The gene discussed is UCHL1; the disease is plasma cell myeloma.